Investor Presentation

Limited Date: November 03, 2026 Ref:- GHL/2026-27/EXCH/72 The General Manager The Manager Dept. of Corporate Services Listing Department BSE Limited, National Stock Exchange of India Limited P J Towers, Dalal Street, Exchange Plaza, C-1, Block G, Mumbai - 400 001 Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Scrip Code: 543654 Symbol: MEDANTA Sub: Investor Presentation Dear Sir(s), Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Investor Presentation for the Second Quarter & Half Year ended September 30, 2026 Results. Kindly take the above on record. Thanking you, Yours faithfully For Global Health Limited Rahul Ranjan Company Secretary & Compliance Officer M.No. A17035 Encl: a/a Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 www.medanta.org, info@medanta.org, CIN: L85110DL2004PLC128319 GLOBAL HEALTH LIMITED Dedicated to Life Investor Presentation Q2 and H1 FY2027 November 3, 2026 Disclaimer This presentation, apart from historical information, contains some "forward-looking statements" including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company. These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes. Contents 01 Q2 and H1 FY2027 Performance Update 02 Project Update and Capex Plan 03 Medanta’s Journey, Purpose and Model of Healthcare 04 Annexures 01 Q2 and H1 FY2027 Performance Update Q2 FY2027 performance summary Revenue Growth of 34% y-o-y driven by growth in patient volumes Occupied Bed Days ARPP* (INR Lakh) ALOS (days) Patient Footfalls (in ‘000) 66 1,229 190,600 2.06 In-patients Out-patients** Q2 FY26 Q2 FY26 29.5% 37.9% 155,729 22.4% 2.01 2.7% Q2 FY26 Q2 FY26 51 891 *ARPP is calculated on Hospital Revenues excluding Other Operating Income and other income divided by Inpatient Volumes; 5 **Outpatients volume reflects OPD encounters morf euneveR snoitarepo Q2 FY26 33.6% 10,993 million 1ADTIBE gnitarepO snigraM INR 3,701 million Margin: 25.2% Q2 FY26 2,310 million 60.2% Margin: 21.0% snigraM meoama ~ INR 14,690 million INR 2,191 million ~ ... Margin: 14.9% ~ Q2 FY26 ~ 1,584 million 38.3% ~ Margin: 14.4% 2.89 ~ Q2 FY26 ~ 3.06 -5.5% ~ 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis Q2 FY2027 performance summary Revenue Growth of 34% y-o-y, primarily led by increase in patient volumes  Q2FY27 revenue from operations of INR 14,690 million; growth of 33.6% y-o-y  Operating EBITDA grew 60.2 % y-o-y to INR 3,701 million with improved margins of 25.2% in Q2 FY27 compared to 21.0% in Q2FY26.  Noida hospital witnessed revenue from operations of INR 1,059 million and EBITDA of INR 86 million in Q2 FY27  Profit After Tax was INR 2,191 million, compared to INR 1,584 million in Q2FY26. PAT margins were at 14.9% compared to 14.4% in Q2 FY26  During the quarter, total 74 new beds were added across the network; 25 beds were added at Lucknow and 49 beds in Noida  Medanta continues to witness robust volume growth, In-patient count grew by 29.5% while Out-patient count grew by 37.9% y-o-y  With the addition of beds across the network over the last 18 months (including Noida launch), Medanta’s Census bed capacity stood at 3,115 in Q2FY27 compared to 2,658 beds in Q2FY26.  Occupied bed days increased by 22.4% y-o-y, representing an occupancy of ~67% on increased bed capacity compared to 64% in Q2FY26.  Average revenue per patient (ARPP) for the quarter was INR 2.06 lakh compared to INR 2.01 lakh in Q2FY26  Average length of stay (ALOS) for the quarter was 2.89 days compared to 3.06 days in previous corresponding quarter  Cluster 1 hospitals (Gurgaon, Indore and Ranchi) reported revenue from operations of INR 8,229 million in Q2FY27, growth of 17.8% y-o-y. Operating EBITDA was INR 1,810 million, growth of 29.1% y-o-y; Operating EBITDA margin expanded to 22.0% from 20.1% in Q2FY26.  Cluster 2 hospitals (Lucknow, Patna and Noida), reported revenue from operations of INR 5,790 million, growth of 63.2% y-o-y. Operating EBITDA increased by 110.0% y-o-y to INR 1,837 million, with margins improving to 31.7% compared to 24.7% in Q2FY26  During the quarter, International Patients Revenue increased by 30.3% y-o-y to INR 993 million  OPD Pharmacy (Hospital & Retail) business continues to witness robust growth. Revenue increased by 52.9% y-o-y to INR 699 million in Q2 FY27 1. EBITDA represents EBITDA before ESOP expenses Q2 FY2027 Business update Strengthening the Core and Building a Robust Pipeline for Sustainable Growth Capacity Expansion New Medical Equipment Deployed  Noida: Added 49 beds; total operational capacity at 482 beds Gurugram Patna  Lucknow: 25 beds added, taking total bed capacity to 803 beds  Ranchi: Launched Medical Oncology services  Gurugram: 2 New OTs and 1 new Cath Lab added during the quarter  Ghaziabad: Allotted 2.61 acre land parcel in an e-auction for VELYS Hip Navigation Station Siemens Artis ArtisIconoBiplane Lab SAT Station INR 1,658.2 mn ceiling-mounted cathlab BAS Station Attract Best Talent Continuity of Care  100+ Doctors on-boarded in Q2 FY27 across Medanta  850+ active collection centres across 120+ cities supported networkhospitals by 13 labs and 7 HLMs /RLMs  65+ senior clinicians on-boardedduring thequarter  Added 6 pharmacies during the quarter, expanding the network to 28 operational pharmacies (7 Hospital, 4 Medi-clinics and 17 Retail Pharmacies) Medanta Noida operational with 482 beds Noida operations demonstrating strong momentum, with EBITDA breakeven achieved during Q2 FY27 Revenue from operations (INR million) Operating EBITDA1 (INR million) 1,059 -199 -236 -321 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q2 FY27 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis. Key operating metrics: Revenue and profitability meoama ~ Operating EBITDA in Q2 and H1 grew by 60% and 43% y-o-y, respectively ~ Revenue from operations (INR million) +30.2%~ + 27,731 21,301 ~+33.6% + ~ 14,690 -13=,041 10,993 ~ H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 Operating EBITDA1 (INR million and margin %) +43.4~% + ~ 6,568 ~+60.2% + 4,580 ~ 3,701 2,868 2,310 H1 FY26 H1 FY27 Q2 FY26 Q1 FY27 Q2 FY27 ~ 21.5% 23.7% 21.0% 22.0% 25.2% ~ 1. Operating EBITDA is defined as EBITDA excluding other income and after accounting for ESOP expenses. The comparative figures have also been presented on a consistent, like-for-like basis Key operating metrics: Profitability and margin meoama ~ Q2 PBT and PAT growth of 48% and 38% y-o-y, respectively ~ Profit before tax (INR million and margin %) ~+24.5% + ~ 5,081 4,080 ~+47.6% + ~ 2,948 2,133 1,998 H1 FY26* cH:1: F:Y:2>7 Q2 FY26* Q1 FY27 cQ:2: :F:Y2>7 c=:> c=:> c=:> 19.2% 18.3% 18.2% 16.4% 20.1% ~ Profit after tax (INR million and margin %) +18.6% ~ 3,764 3,174 c=:> +3 [Showing first 8,000 characters — download PDF for full document]